Logo
ABBV logo
AbbVie Inc.
ABBV
256.46 (-1.41%) 3.62
Market cap
$453.19(B)
Earnings date
Oct-29-2026
Category
Sector
Health Care
Industry
Biotechnology
AbbVie Inc. a research-based biopharmaceutical company engages in the research and development manufacturing commercializing and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables plastics and regenerative medicine body contouring and skincare products; botox Cosmetic for the treatment of glabellar lines crow's feet forehead lines and platysma bands; Juvederm Collection to treat volume loss in the temples undereye cheeks chin lips and lower face; Vraylar to treat schizophrenia bipolar disorder and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations as well as Botox Therapeutic to treat chronic migraine overactive bladder spasticity cervical dystonia and other conditions. In addition the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products including Refresh/Optive Xen Durysta and Restasis. Further it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago Illinois.
EV: $528.15(B)
Total Equity: $-5.89(B)
Debt/Equity: 48
Dividend/share: $6.8
Div. yield: 2.66%
P/E: 72.45
Forward P/E: 18.31
P/FCF: 24.87
P/S: 7.05
P/B: N/A
EPS: $3.5
EPS (fwd): $14.0
FCF/share: $10.3
Revenue/share: $36.4
Book value/share: $-3.4
ROIC: 3.3%
ROA: 1.7%
ROE: 140.9%
Margins: Gross | Op. | Net
72.8% | 24.1% | 9.8%
0.0%of Portfolio
My holdings
Day change
Total change
Overview Valuation Growth Financials & KPIsCompetitors & Peer Comparison Ownership ToolsAll

Ownership

Major holders

*Excludes indirect insider ownership

Insiders: 0.11%
Institutions: 77.07%
Other: 22.82%

Institutional ownership

8.46% Blackrock Inc.6.50% Vanguard Capital Manag...4.67% State Street Corporati...3.21% JPMORGAN CHASE & CO2.80% Vanguard Portfolio Man...2.65% Geode Capital Manageme...2.15% Morgan Stanley1.77% Capital Research Globa...1.35% Bank of America Corpor...1.23% FMR, LLC42.28% Others

Trading Summary

In the past year, insiders have sold a net of $10.74(M).

Total insider buys: $0.00
Total insider sells: $10.74(M)

In the past year, Congress members have sold a net of $56502.

Total congressional buys (avg): $32002
Total congressional sells (avg): $88504

Based on the reported ranges: buys $4004–$60000, sells $22008–$155000.

Insider transactions

$0.002026-10$0.00
$0.002026-09$0.00
$0.002026-08$0.00
$0.002026-07$0.00
$0.002026-06$0.00
$0.002026-05$0.00
$0.002026-04$0.00
$5.60(M)2026-03$0.00
$5.15(M)2026-02$0.00
$0.002026-01$0.00
$0.002025-12$0.00
$0.002025-11$0.00
$0.002025-10$0.00
DateSharesTotal ($)Price ($)NameTitle
Grant2026-05-081,11800.0RAPP EDWARD JDirector
Grant2026-05-081,11800.0HART BRETT JDirector
Grant2026-05-081,11800.0BURNSIDE WILLIAM H LDirector
Grant2026-05-081,11800.0MEYER MELODY BDirector
Grant2026-05-081,11800.0ROBERTS REBECCA B.Director
Grant2026-05-081,11800.0DAVIS JENNIFER LDirector
Grant2026-05-081,11800.0QUAGGIN SUSAN EDirector
Grant2026-05-081,11800.0FREYMAN THOMAS CDirector
Grant2026-05-081,11800.0FALK THOMAS JDirector
Grant2026-05-081,11800.0AUSTIN ROXANNE SCHUHDirector
Grant2026-05-081,11800.0WADDELL FREDERICK HDirector
Sell2026-03-045,2301,221,519233.6PURDUE DAVID RYANOfficer
Sell2026-03-0218,6684,375,549234.4SIATIS PERRY C.General Counsel
Grant2026-02-2522,3813,863,458172.6SIATIS PERRY C.General Counsel
Sell2026-02-2522,3815,147,630230.0SIATIS PERRY C.General Counsel
Grant2026-02-1836,81100.0SALEKI-GERHARDT AZITAChief Operating Officer
Grant2026-02-1882,43900.0MICHAEL ROBERT A.Chief Executive Officer
Grant2026-02-1853,74900.0STEWART JEFFREY RYANOfficer
Grant2026-02-1829,05700.0DONOGHOE NICHOLASOfficer
Grant2026-02-1848,83800.0REENTS SCOTT T.Chief Financial Officer
Grant2026-02-1833,51800.0SIATIS PERRY C.General Counsel
Grant2026-02-1818,13700.0THAKKAR ROOPALOfficer
Grant2026-02-186,07100.0PURDUE DAVID RYANOfficer
Grant2026-02-182,46000.0CRUM DEMETRIS DOfficer

Congressional trading

$0.002026-10$0.00
$0.002026-09$0.00
$0.002026-08$0.00
$0.002026-07$0.00
$0.002026-06$0.00
$0.002026-05$0.00
$0.002026-04$0.00
$0.002026-03$0.00
$0.002026-02$0.00
$325012026-01$8001
$160012025-12$0.00
$80012025-11$0.00
$80012025-10$24002
DatePoliticianPartyChamberAmount ($)
Sell2026-01-29Ro KhannaDHouse$15,001 - $50,000
Buy2026-01-23Ro KhannaDHouse$1,001 - $15,000
Sell2025-12-18Julie JohnsonDHouse$1,001 - $15,000
Sell2025-12-08Julia LetlowRHouse$1,001 - $15,000
Sell2025-11-13Julie JohnsonDHouse$1,001 - $15,000
Buy2025-10-30Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-10-30Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-10-30Lisa C. McClainRHouse$1,001 - $15,000
Sell2025-10-30Lisa C. McClainRHouse$1,001 - $15,000
Sell2025-08-22John BoozmanRSenate$1,001 - $15,000
Sell2025-08-14Julie JohnsonDHouse$1,001 - $15,000
Sell2025-08-11John BoozmanRSenate$1,001 - $15,000
(C) PEVALUATOR
About
Terms & privacy
Price charts & news courtesy of TradingView
Blog
Contact